Modified AAV Capsid for Inner Ear Hair Cell Infection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current inner ear gene therapy methods face low infection efficiency in hair cells and supporting cells, limiting their effectiveness in treating hearing loss and dizziness.

Innovation Solution

A recombinant adeno-associated virus (AAV) virion with a modified capsid protein containing a peptide insertion (LGETTRP) is used to enhance infection efficiency in inner ear hair cells, delivering genetic material to reduce hearing loss and dizziness by targeting specific genes associated with these conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional AAV vectors are used for inner ear gene therapy, then the therapy can be administered, but the infection efficiency in hair cells and supporting cells remains low

Engineering Contradiction:
Improveinfection efficiencyVSAvoidtherapeutic effectiveness
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent applies parameter changes by modifying the amino acid sequence of the AAV capsid protein. Specifically, amino acid residues at positions 587-588 of the VP1 capsid protein are mutated (e.g., to LGETTRP sequence), which changes the physical-chemical properties of the capsid surface. This parameter modification enables the viral vector to efficiently infect inner ear hair cells and supporting cells that were previously resistant to conventional AAV vectors.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If the AAV capsid protein is modified to improve hair cell infection, then infection efficiency increases, but the complexity of vector design and manufacturing increases

Engineering Contradiction:
Improveinfection efficiencyVSAvoidvector design complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by making targeted, localized modifications to specific regions of the AAV capsid protein rather than redesigning the entire vector. The mutation is confined to a specific epitope region (amino acids 587-588 of VP1), allowing the rest of the capsid structure to remain intact and functional. This localized approach improves hair cell infection while minimizing the complexity increase compared to comprehensive vector redesign.

Inventive Principle:
Principle #3Local quality

Data Source

PatentUS20220096658A1Adeno-associated viruses and their uses for inner ear therapy
Publication Date: 2022.03.31 THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
  • US20220096658A1 patent drawing
  • US20220096658A1 patent drawing
  • US20220096658A1 patent drawing

AI summary

Provided herein are adeno-associated viruses and methods for using same to treat or prevent disorders that affect the inner ear of a subject.